In conclusion, when highly sensitive methods such as dPCR or next-generation sequencing (NGS) are introduced into clinical practice in the near future, T790M will be detected with a high frequency in NSCLC cases positive for activating EGFR mutations regardless of whether the patient has been treated with EGFR-TKIs or not. Here, EGFR is linked to non-small cell lung carcinoma.